/PRNewswire/ Minimal Residual Disease Testing Market is valued at an estimated USD 1.2 Billion in 2022 and is projected to reach USD 2.3 Billion by 2027, at.
WINTON GROUP Ltd lifted its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Rating) by 29.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,476 shares of the company’s stock after acquiring an additional 5,597 shares during the quarter. WINTON […]
TD Asset Management Inc. lessened its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Rating) by 49.4% in the first quarter, Holdings Channel reports. The institutional investor owned 91,119 shares of the company’s stock after selling 88,953 shares during the period. TD Asset Management Inc.’s holdings in Adaptive Biotechnologies were worth $1,265,000 at the end […]
Advisor Group Holdings Inc. lowered its stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Rating) by 5.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,467 shares of the company’s stock after selling 2,826 shares during the period. Advisor […]